SLC5A2 and chronic kidney disease: A nationwide, multicenter study (J-CKD-DB) found that SGLT2 inhibitors slowed eGFR decline (−0.47 vs. −1.22 mL/min/1.73 m2/year, p < 0.001), with an absolute difference of 0.75 mL/min/1.73 m2/year [54].